Immunotherapy of Cancer (Cancer Drug Discovery and Development)

Major scientific advances in molecular and clinical immunology have produced tremendous growth in our understanding of how cancer is recognized by the immune system, as well as in our ability to control and modulate that recognition. In Immunotherapy of Cancer, expert bench and clinical scientists join forces to concurrently review both the state of the art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cytokines, vaccines, and T-cells, and illustrate their clinical manipulation to combat cancer. Additional chapters address statistical analysis-both of clinical trials and assay evaluations-methods for the discovery of antigens, adoptive T-cell therapy, and adaptive and innate immunity. The challenges in clinical trial design, the need for biomarkers of response-such as novel imaging techniques and immunological monitoring-and the new advances and directions in cancer immunotherapy are also fully examined. Comprehensive and cutting-edge, Immunotherapy of Cancer offers immunologists an exhaustive and authoritative survey of cancer immunotherapy, as well as providing a springboard for applying the most important findings in tumor immunology to any basic laboratory program or clinical oncology practice. Front Matter....Pages i-xii Discovery of Target Molecules for Cancer Immunotherapy by Genetic and Bioinformatic Approaches....Pages 1-19 Current Strategies for the Identification of Immunogenic Epitopes of Tumor Antigens....Pages 21-44 Current and Future Role of Natural-Killer Cells in Cancer Immunotherapy....Pages 45-58 The Role of Immune Monitoring in Evaluating Cancer Immunotherapy....Pages 59-72 Statistical Analysis of Immune Response Assays in Cancer Immunotherapy Trials....Pages 73-85 DNA Vaccines for Cancer Immunotherapy....Pages 87-114 Dendritic Cells....Pages 115-126 Different Approaches to Dendritic Cell-Based Cancer Immunotherapy....Pages 127-138 Anti-Idiotype Antibody Vaccines for the Immunotherapy of Cancer....Pages 139-149 Autologous Tumor-Derived Heat Shock Protein Vaccine as a New Paradigm for Individualized Cancer Therapeutics....Pages 151-166 Tumor-Reactive T-Cells for Adoptive Immunotherapy....Pages 167-179 T-Cell Adoptive Immunotherapy of Cancer....Pages 181-212 Retroviral-Mediated Gene Transfer for Engineering Tumor-Reactive T-Cells....Pages 213-233 Harnessing the Potential of Graft-vs-Tumor....Pages 235-261 Tumor-Induced Immune Suppression and Immune Escape....Pages 263-284 The Tumor Microenvironment....Pages 285-301 Manipulation of Lymphocyte Homeostasis for Enhancing Antitumor Immunity....Pages 303-316 Fast-Lane Evolution in the Tumor Microenvironment....Pages 317-329 Manipulating Immunological Checkpoints to Maximize Antitumor Immunity....Pages 331-353 Interleukin-2 as Cancer Therapy....Pages 355-364 Biological and Clinical Properties of the Type 1 Interferons....Pages 365-396 Promising γ-Chain Cytokines for Cancer Immunotherapy....Pages 397-414 The Therapeutic Use of Natural-Killer Cells in Hematological Malignancies....Pages 415-432 Antibody Therapy for Solid Tumors....Pages 433-444 Antibody Therapy for Non-Hodgkin’s Lymphoma....Pages 445-455 Approaches to In Vivo Imaging of Cancer Immunotherapy....Pages 457-477 Design Issues for Early-Stage Clinical Trials for Cancer Vaccines....Pages 479-485 Monoclonal Antibody Therapy of Cancer....Pages 487-502 Back Matter....Pages 503-516 Discovery Of Target Molecules For Cancer Immunotherapy By Genetic And Bioinformatic Approaches -- Current Strategies For The Identification Of Immunogenic Epitopes Of Tumor Antigens -- Current And Future Role Of Natural-killer Cells In Cancer Immunotherapy -- The Role Of Immune Monitoring In Evaluating Cancer Immunotherapy -- Statistical Analysis Of Immune Response Assays -- Dna Vaccines For Cancer Immunotherapy -- Dendritic Cells -- Different Approaches To Dendritic Cell-based Cancer Immunotherapy -- Anti-idiotype Antibody Vaccines For The Immunotherapy Of Cancer -- Autologous Tumor-derived Heat Shock Protein Vaccine As A New Paradigm For Individualized Cancer Therapeutics -- Tumor-reactive T-cells For Adoptive Immunotherapy -- T-cell Adoptive Immunotherapy Of Cancer: From Translational Models To Clinical Significance -- Retroviral-mediated Gene Transfer For Engineering Tumor-reactive T-cells -- Harnessing The Potential Of Graft-vs-tumor -- Tumor-induced Immune Suppression And Immune Escape: Mechanisms And Impact On The Outcome Of Immunotherapy Of Malignant Disease -- The Tumor Microenvironment: Regulation Of Antitumor Immunity And Implications For Immunotherapy -- Manipulation Of Lymphocyte Homeostasis For Enhancing Antitumor Immunity -- Fast-lane Evolution In The Tumor Microenvironment -- Manipulating Immunological Checkpoints To Maximize Antitumor Immunity -- Interleukin-2 As Cancer Therapy -- Biological And Clinical Properties Of The Type 1 Interferons -- Promising G [gamma]-chain Cytokines For Cancer Immunotherapy: Interleukins-7, -15, And -21 As Vaccine Adjuvants, Growth Factors -- The Therapeutic Use Of Natural-killer Cells In Hematological Malignancies -- Antibody Therapy For Solid Tumors -- Antibody Therapy For Non-hodgkin's Lymphoma -- Approaches To In Vivo Imaging Of Cancer Immunotherapy -- Design Issues For Early-stage Clinical Trials For Cancer Vaccines -- Monoclonal Antibody Therapy For Cancer. Edited By Mary L. Disis. Includes Bibliographical References And Index. Mode Of Access: World Wide Web. Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cytokines, vaccines, and T-cells, and illustrate their clinical manipulation to combat cancer. Additional chapters address statistical analysis-both of clinical trials and assay evaluations-methods for the discovery of antigens, adoptive T cell therapy, and adaptive and innate immunity. The challenges in clinical trial design, the need for biomarkers of response-such as novel imaging techniques and immunologic monitoring-and the new advances and directions in cancer immunotherapy are also fully examined. Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cytokines, vaccines, and T-cells, and illustrate their clinical manipulation to combat cancer. Additional chapters address statistical analysis - both of clinical trials and assay evaluations - methods for the discovery of antigens, adoptive T cell therapy, and adaptive and innate immunity. The challe